Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction

References

• Okuda M. A multidisciplinary overview of cardiogenic shock. Shock 2006; 25: 557–70
   PubMedGoogle Scholar
• Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005; 294: 448–54
   PubMed Web of Science ®Google Scholar
• Lehtonen L, Poder P. The utility of levosimendan in the treatment of heart failure. Ann Med. 2007; 39: 2–17
   PubMed Web of Science ®Google Scholar
• Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006; 104: 556–69
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196–202
   PubMed Web of Science ®Google Scholar
• Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002; 23: 1422–32
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883–891
   PubMed Web of Science ®Google Scholar
• Parissis JT, Farmakis D, Nieminen M. Classical inotropes and new cardiac enhancers. Heart Fail Rev. 2007; 12: 149–56
   PubMed Web of Science ®Google Scholar
• Delle-Karth G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C, et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand. 2003; 47: 1251–6
   PubMedGoogle Scholar
• Plochl W, Rajek A. The use of the novel calcium sensitizer levosimendan in critically ill patients. Anaesth Intensive Care 2004; 32: 471–5
   PubMedGoogle Scholar
• Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit. 2004; 10: MT89–93
   PubMed Web of Science ®Google Scholar
• Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ, Abreu-Gonzalez P, Munoz MB. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail. 2006; 8: 723–8
   PubMed Web of Science ®Google Scholar
• Rokyta R, Jr, Pechman V. The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock. Neuro Endocrinol Lett. 2006; 27: 121–7
   PubMed Web of Science ®Google Scholar
• De Luca L, Fonarow GC, Mebazaa A, Shin DD, Collins SP, Swedberg K, et al. Early pharmacological treatment of acute heart failure syndromes: A systematic review of clinical trials. Acute Card Care 2007; 9: 10–21
   PubMedGoogle Scholar
• Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102: 2222–7
   PubMed Web of Science ®Google Scholar
• Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail. 2007; 9: 75–82
   PubMed Web of Science ®Google Scholar
• De Luca L, Proietti P, Celotto A, Bucciarelli-Ducci C, Benedetti G, Di Roma A, et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J. 2005; 150: 563–8
   PubMed Web of Science ®Google Scholar
• Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005; 31: 638–44
   PubMed Web of Science ®Google Scholar
• Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Soffker G, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med. 2007; 35: 2732–9
   PubMed Web of Science ®Google Scholar
• Parissis JT, Farmakis D, Bistola V, Adamopoulos S, Kremastinos DT. Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients. Am J Cardiol. 2007; 99: 146–7
   PubMed Web of Science ®Google Scholar
• Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006; 98: 102–6
   PubMed Web of Science ®Google Scholar
• Urban P, Stauffer JC, Bleed D, Khatchatrian N, Amann W, Bertel O, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) multicenter trial of angioplasty for shock-(S)MASH. Eur Heart J. 1999; 20: 1030–8
   PubMed Web of Science ®Google Scholar
• Samimi-Fard S, Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Abreu-Gonzalez P. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol. 2007; doi: 10.1016/j.ijcard.2007.04.143.
   Google Scholar
• Tasouli A, Papadopoulos K, Antoniou T, Kriaras I, Stavridis G, Degiannis D, et al. Efficacy and safety of perioperative infusion of levosimendan in patients with compromised cardiac function undergoing open-heart surgery: Importance of early use. Eur J Cardiothorac Surg. 2007; 32: 629–33
   PubMedGoogle Scholar